TapImmune Won't Settle for the Moon - BrokerBank Securities
Jun 24, 2015, 07:00 ET
NEW YORK, June 24, 2015 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) a clinical-stage immunotherapy company engaged in the development of peptide, gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, recently announced that its largest shareholder, Eastern Capital Limited, converted $2.5 million equivalent of warrants with immediate infusion into the company's balance sheet. The cash will be used to begin Phase II trials in the upcoming year. In addition, Eastern Capital still holds warrants which if fully exercised could result in an additional $15 million in proceeds to the Company. As part of the previously announced warrant reset strategy, other institutional holders hold warrants which if exercised could provide additional significant funding to the Company in the near-term.
Management has employed a strategy intended to rebuild its balance sheet and was successful. Investor surely thought the same by rewarding the company with significant volume and price appreciation.
For a more detailed research report with analyst comments and recommendation on TapImmune Inc. please follow the link. There is no cost obligation required to view analyst brief.
Copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report. This document, article or report is written and authored by a 3rd party research analyst. However, we are only human and make mistakes. If you notice any errors or omissions, please notify us below.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.
Share this article